David A. Siegel Ptc Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ptc Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 360,442 shares of PTCT stock, worth $18.2 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
360,442
Previous 429,842
16.15%
Holding current value
$18.2 Million
Previous $15.9 Million
2.03%
% of portfolio
0.04%
Previous 0.04%
Shares
26 transactions
Others Institutions Holding PTCT
# of Institutions
257Shares Held
77.3MCall Options Held
179KPut Options Held
536K-
Vanguard Group Inc Valley Forge, PA9.18MShares$462 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.77MShares$392 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.39MShares$372 Million5.44% of portfolio
-
Armistice Capital, LLC New York, NY6.38MShares$321 Million4.07% of portfolio
-
Wellington Management Group LLP Boston, MA4.79MShares$241 Million0.04% of portfolio
About PTC THERAPEUTICS, INC.
- Ticker PTCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,541,000
- Market Cap $3.6B
- Description
- PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on...